Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the duration of survival between patients
receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients
receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer
respond to hormone therapy, who have documented metastases with pain. Patients may have had
up to one prior non-taxane chemotherapy treatment.